Xtalks Announces its Life Science Webinar Calendar for August 2025
Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain and preclinical.
Visit www.xtalks.com to see our upcoming webinars:
CELL AND
CLINICAL TRIALS
COMMERCIALIZATION & HEOR
DRUG DISCOVERY & DEVELOPMENT
HEALTHCARE
LABORATORY TECHNOLOGY
MEDICAL DEVICE
PATIENT RECRUITMENT & RETENTION
PHARMA MANUFACTURING & SUPPLY CHAIN
PRECLINICAL
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit www.xtalks.com.
Contact:
Xtalks (www.xtalks.com)
Tel: +1 (416) 977-6555 x371
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/xtalks-announces-its-life-science-webinar-calendar-for-august-2025-302519782.html
SOURCE Xtalks
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Husqvarna Brings Autonomous Mowing to the 2026 U.S. Senior Women's Open
- GLOBAL EQUITY TOKENIZATION ENTERS CRITICAL IMPLEMENTATION PHASE AHEAD OF OCTOBER DTC LAUNCH, NEW TFOS RESEARCH FINDS
- Vessev Enters U.S. Market With $19 Million Series A, Names First U.S. Customer And Launches Multi-City U.S. Showcase
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share